查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1916905

江之灵片市场：按产品类型、治疗领域、生产商类型、通路和最终用户划分－2026-2032年全球预测

Jiangzhiling Tablets Market by Product Type, Therapeutic Area, Manufacturer Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，江之灵片剂市场价值将达到 9,386 万美元，到 2026 年将成长至 1.0451 亿美元，到 2032 年将达到 1.2603 亿美元，复合年增长率为 4.30%。

关键市场统计数据
基准年 2025 9386万美元
预计年份：2026年 1.0451亿美元
预测年份 2032 1.2603亿美元
复合年增长率 (%) 4.30%

对江之灵片进行深入分析，分析内容涵盖临床需求、製剂特性以及影响其策略选择的商业性环境。

江之灵片凭藉其独特的製剂特性和标靶治疗治疗应用，已成为心血管和代谢治疗领域独树一帜的治疗方法，吸引了临床医生、支付方和生产商的广泛关注。随着治疗模式日益重视患者依从性和差异化释放曲线，江之灵片的市场定位恰好满足了临床对持续疗效的需求和商业性上对可靠供应的迫切需求。本介绍将产品置于更广泛的治疗需求、监管审查和分销复杂性的背景下，说明读者了解战略决策背后的关键考虑因素。

更严格的监管、多元化的通路以及以患者为中心的製剂优先策略将如何重塑江之灵片的商业性和临床格局

由于监管政策的变化、通路的演变以及供应链监管的加强，循环系统药物和口服药锭市场格局正在变革性变化。新的生产模式优先考虑在地化生产的灵活性和日益严格的品管，而数位化管道的兴起则持续加剧通路的碎片化。这些变化正在重塑江之灵等产品的研发、核准和交付方式，需要研发、生产和商业化等各个环节的相关人员做出相应的调整。

评估截至2025年的关税如何加强了江之菱价值链的供应链重组、筹资策略和製造本地化决策。

主要经济体实施的关税政策将持续到2025年，这进一步增加了药品供应链的复杂性，影响成本、采购决策和策略性製造地。对于依赖进口原料药和成品药的产品而言，关税相关的附加税和合规要求正在增加采购成本，并促使企业重新评估供应商网路。为此，许多製造商正在评估近岸外包的可行性，以加快供应商选择流程并降低贸易政策波动的风险。

要了解江之灵片市场，需要建立一套严谨的市场区隔框架，以揭示通路、患者群体、剂型、治疗标靶和生产商概况如何影响策略重点。

要了解江之灵片市场，需要深入分析通路、终端用户群、产品类型、治疗应用和製造商类型等因素，这些因素都会对商业策略产生不同的影响。分销管道涵盖医院药房、线上药房和零售药房，其中医院主导着组织采购流程，而线上管道则加快了患者获取药物的便利性。终端使用者因素则区分成人、老年人和儿童病患群体，进而影响临床讯息、给药方案和依从性计画。

区域监管差异、报销结构和生产能力如何影响江之灵片的打入市场策略和供应链策略

区域趋势将对江之灵片的监管路径、报销机制和供应链设计产生重大影响，每个区域都面临独特的营运和商业挑战。在美洲，严格的监管、激烈的医保谈判以及经销商的高度参与共同影响着市场趋势，促使企业更加重视临床证据和强有力的药物监测，以确保产品被纳入处方集目录。同时，在欧洲、中东和非洲地区，监管协调与分散的医保体系并存，市场格局呈现出多元化的特点，企业需要製定能够应对各国采购和定价差异的适应性策略。

竞争格局分析表明，原厂品牌、国内外学名药以及製剂技术是决定差异化和商业性发展势头的关键因素。

江津地区的竞争格局由成熟的原厂药品牌和不断扩张的非专利市场共同构成，二者各自提出了不同的策略要务。原厂药品牌往往专注于差异化的临床证据、全生命週期管理和高端定位，而非专利优先考虑成本竞争力、生产效率和建立广泛的分销网络。在学名药领域，国内生产商倾向于利用低成本营运和接近性在地采购管道的优势，而进口学名药则可能透过提升品牌知名度、规范合规记录或製剂技术来脱颖而出。

切实可行的策略重点，将配方创新、供应链韧性和通路特定的商业执行相结合，以确保竞争优势。

产业领导者应采取整合策略，将製剂创新、供应链韧性和精准的商业性执行结合，以把握机会并降低风险。优先投资于缓释製剂的研发可以带来显着的临床优势和用药依从性提升，但必须辅以严格的稳定性测试和清晰的临床沟通差异化。同时，供应商网路多元化和评估近岸外包方案可以降低贸易政策波动带来的风险，并使原料药和成品的前置作业时间更加可预测。

采用严谨的混合方法，结合与关键相关人员的直接对话、二次三角验证和情境检验，以确保研究结果的稳健性和有效性。

本分析的调查方法结合了与主要相关人员的对话以及全面的第二手资料综合分析，以确保对江之灵的市场环境有全面而深入的了解。一级资讯来源包括对临床专家、供应链经理和商业负责人的结构化访谈，以获取有关处方行为、采购趋势和营运限制的第一手资讯。随后，将这些定性研究结果与监管文件、已发表的临床文献和产品检验进行三角验证，以检验技术和安全性声明。

配方差异化、供应链韧性和精准商业化如何决定江之灵永续市场表现的策略整合分析

总之，江之灵片的市场环境是这样的：基于製剂特性的临床机会与重要的商业性营运挑战交织在一起。缓释技术和製剂改良为高血脂症和高血压等治疗领域的差异化提供了途径，但成功取决于临床证据、法规遵循和可靠的供应链的综合运用。通路和终端用户的多样性进一步要求制定细緻打入市场策略，以平衡机构采购週期与零售药局和线上药局日益增长的影响力。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 江之灵片剂市场（依产品类型划分）

  • 缓释片
    • 0.5克强度
    • 1克强度
  • 标准片剂
    • 0.5克强度
    • 1克强度

第九章 江之灵片市场依治疗领域划分

  • 高血脂症
  • 高血压

第十章 江之灵片市场（依生产商类型划分）

  • 学名药
    • 国产学名药
    • 进口学名药
  • 原品牌

第十一章 江之灵片市场通路

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 江之灵片剂市场（依最终用户划分）

  • 成人
  • 老年人
  • 儿童

第十三章 江之灵片市场区域划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 江之灵片市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 江之灵片市场各国状况

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章美国江之灵片市场

第十七章：中国抗芝灵片市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Anhui Shengkang Pharmaceutical Co., Ltd.
  • Beijing Tong Ren Tang Co., Ltd.
  • Harbin Pharmaceutical Group Co., Ltd.
  • Jiangsu Kanion Pharmaceutical Co., Ltd.
  • Jilin Yatai Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Group Inc.
  • Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  • Tasly Pharmaceutical Group Co., Ltd.
  • Yunnan Baiyao Group Co., Ltd.
  • Zhejiang Conba Pharmaceutical Co., Ltd.
Product Code: MRR-AE420CB153E5

The Jiangzhiling Tablets Market was valued at USD 93.86 million in 2025 and is projected to grow to USD 104.51 million in 2026, with a CAGR of 4.30%, reaching USD 126.03 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 93.86 million
Estimated Year [2026] USD 104.51 million
Forecast Year [2032] USD 126.03 million
CAGR (%) 4.30%

An insightful orientation that contextualizes Jiangzhiling tablets within clinical needs, formulation attributes, and the commercial landscape influencing strategic choices

Jiangzhiling tablets have emerged as a distinctive therapy within cardiovascular and metabolic treatment regimens, attracting attention from clinicians, payers, and manufacturers due to their formulation characteristics and targeted therapeutic use. As treatment paradigms evolve toward greater emphasis on patient adherence and differentiated release profiles, Jiangzhiling's positioning intersects clinical demand for sustained efficacy with commercial imperatives for reliable supply. This introduction frames the product in the broader context of therapeutic need, regulatory scrutiny, and distribution complexity, guiding readers through the salient considerations that underpin strategic decisions.

To set the stage for subsequent analysis, it is important to consider the interplay between formulation science and market reception. Clinical stakeholders increasingly prioritize products that deliver predictable pharmacokinetics while minimizing dosing burden, and manufacturers must navigate intellectual property landscapes, manufacturing scalability, and evolving quality expectations. Transitioning from therapeutic rationale to commercial realities, the remainder of this report unpacks the structural forces shaping Jiangzhiling's trajectory and translates them into actionable perspectives for executives and portfolio managers.

How regulatory rigor, channel diversification, and patient-centric formulation priorities are reshaping the commercial and clinical landscape for Jiangzhiling tablets

The landscape surrounding cardiovascular therapeutics and oral tablet formulations is undergoing transformative shifts driven by regulatory change, channel evolution, and heightened supply chain scrutiny. New manufacturing paradigms prioritize localized production resilience and compliance with increasingly stringent quality controls, while distribution pathways continue to fragment as digital channels gain traction. These shifts are reshaping how products like Jiangzhiling are developed, approved, and delivered to patients, requiring stakeholders to adapt across research, manufacturing, and commercialization functions.

Converging with manufacturing and channel dynamics, payer expectations and prescriber preferences are evolving toward evidence of real-world effectiveness and adherence benefits. Patient-centric design, including extended-release formulations that reduce dosing frequency, is influencing prescriber choice and formulary placement. Moreover, regulatory authorities are intensifying scrutiny of manufacturing consistency and supply chain traceability, prompting firms to invest in robust quality systems and supplier diversification. As a result, the competitive environment is no longer defined solely by clinical efficacy but also by an ability to demonstrate reliable supply, regulatory compliance, and measurable patient outcomes.

Assessing how tariff measures through 2025 have intensified supply chain recalibration, procurement strategy, and manufacturing localization decisions across the Jiangzhiling value chain

Tariff policies implemented by major economies through 2025 have introduced additional layers of complexity for pharmaceutical supply chains, affecting costs, sourcing decisions, and strategic manufacturing footprints. For products dependent on imported active pharmaceutical ingredients or finished dosage forms, tariff-related duties and associated compliance requirements have increased procurement overhead and prompted re-evaluation of supplier networks. In response, many manufacturers have accelerated supplier qualification initiatives and assessed the viability of nearshoring to mitigate exposure to trade policy volatility.

Beyond cost implications, tariffs have influenced decisions around inventory strategy and contractual terms with raw material providers. Firms have adjusted procurement lead times, increased safety stock in certain geographies, and negotiated price and delivery contingencies to preserve continuity of supply. Simultaneously, policy-driven shifts have altered competitive dynamics by favoring manufacturers with domestic production capabilities or vertically integrated supply chains. Taken together, the cumulative effect of tariff measures has been to sharpen focus on supply chain resilience, pricing strategy, and the strategic alignment of manufacturing footprints with key commercial markets.

A nuanced segmentation framework revealing how distribution pathways, patient cohorts, formulation types, therapeutic targets, and manufacturer profiles shape strategic priorities for Jiangzhiling

Understanding the Jiangzhiling tablets market requires a granular view of distribution, end-user segments, product typologies, therapeutic applications, and manufacturer archetypes, each of which exerts distinct influence on commercial strategy. Distribution channel dynamics span hospital pharmacies, online pharmacies, and retail pharmacies, with hospitals often driving institutional procurement cycles while online channels accelerate patient access and convenience. End-user considerations differentiate adults, geriatric patients, and pediatric populations, shaping clinical messaging, dosing regimens, and adherence programs.

Product type segmentation distinguishes extended-release tablets from standard tablets, and within those categories, strength variations such as 0.5 gram and 1 gram formulations have implications for prescribing patterns, dosing flexibility, and inventory management. Therapeutic area focus on hyperlipidemia and hypertension informs clinical positioning, evidence generation priorities, and payer negotiations. Manufacturer type, split between generics and original brands, further differentiates market behavior; generics can be sourced domestically or imported, which creates divergent cost structures, regulatory pathways, and market access strategies. By synthesizing these dimensions, stakeholders can identify where competitive advantage is most likely to emerge and which commercial levers will have the greatest impact on adoption and retention.

How regional regulatory diversity, reimbursement structures, and manufacturing capabilities influence tailored market entry and supply chain strategies for Jiangzhiling tablets

Regional dynamics materially influence regulatory pathways, reimbursement mechanisms, and supply chain design for Jiangzhiling tablets, with each geography presenting unique operational and commercial considerations. In the Americas, market behavior is influenced by a combination of regulatory rigor, payer negotiation intensity, and a high degree of distributor involvement, prompting firms to emphasize clinical evidence and robust pharmacovigilance to secure formulary placement. Conversely, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts coexist with fragmented reimbursement systems, requiring adaptive strategies that account for country-level variations in procurement and pricing.

Asia-Pacific markets exhibit diverse manufacturing capabilities and a strong emphasis on domestic production in several economies, alongside rapid growth in digital dispensing channels. These regional differences necessitate differentiated approaches: supply chain localization and partnership models for the Americas and Asia-Pacific, and flexible pricing and market access strategies for Europe, Middle East & Africa. Transitioning between regions, firms must balance centralized programmatic efficiencies with localized execution to address regulatory, commercial, and logistical nuances that affect uptake and sustainability.

Competitive landscape analysis emphasizing how original brands, domestic and imported generics, and formulation capabilities determine differentiation and commercial momentum

Competitive dynamics across the Jiangzhiling landscape are shaped by a mix of established original brands and an expanding generics sector, each driving different strategic imperatives. Original brands tend to concentrate on differentiated clinical evidence, lifecycle management, and premium positioning, while generics prioritize cost competitiveness, manufacturing efficiency, and broad distribution reach. Within the generics category, domestic producers often leverage lower operational costs and proximity to local procurement channels, whereas imported generics may differentiate on perceived quality, regulatory pedigree, or formulation expertise.

Firms that prioritize extended-release technologies are investing in formulation engineering and stability studies to support claims of improved adherence and pharmacokinetic benefits. Meanwhile, companies operating across multiple distribution channels are optimizing commercial models to address physician, institutional, and consumer touchpoints. Collaboration between manufacturers and channel partners is increasingly important, as coordinated efforts on educational programs, supply continuity, and regulatory compliance enhance both adoption and patient outcomes. Overall, competitive advantage emerges from a blend of technical capability, regulatory agility, and distribution execution.

Actionable strategic priorities for leaders to synchronize formulation innovation, supply chain resilience, and channel-focused commercial execution to secure competitive advantage

Industry leaders should pursue an integrated strategy that aligns formulation innovation, supply chain resilience, and targeted commercial execution to capture opportunity and mitigate risk. Prioritizing investment in extended-release formulation development can yield meaningful clinical and adherence advantages, but must be supported by rigorous stability testing and clear differentiation in clinical communication. At the same time, diversifying supplier networks and assessing nearshoring options will reduce exposure to trade policy volatility and enable more predictable lead times for active ingredients and finished products.

Commercially, optimizing channel strategies requires balancing institutional engagement with hospital pharmacies and tailored outreach to retail and online pharmacies to support both prescriber adoption and patient access. Manufacturers should also refine segmentation-based value propositions that reflect differences across adult, geriatric, and pediatric populations, and calibrate messaging for therapeutic contexts such as hyperlipidemia and hypertension. Finally, forming strategic alliances with distributors, contract manufacturers, and clinical research partners can accelerate market entry and strengthen compliance frameworks, delivering a robust platform for sustained growth.

A rigorous mixed-methods approach combining primary stakeholder engagement, secondary source triangulation, and scenario testing to ensure robust and defensible insights

The research methodology underpinning this analysis combines primary stakeholder engagement with comprehensive secondary synthesis to ensure a balanced and defensible understanding of the Jiangzhiling landscape. Primary inputs included structured interviews with clinical experts, supply chain managers, and commercial leaders to capture firsthand perspectives on prescribing behavior, procurement dynamics, and operational constraints. These qualitative insights were triangulated against regulatory documentation, publicly available clinical literature, and product labeling to validate technical and safety narratives.

Analytical rigor was maintained through cross-validation of data points, scenario analysis to test sensitivity to policy and supply disruptions, and iterative peer review by subject matter experts. The approach emphasized transparency in assumptions, systematic treatment of segmentation variables such as distribution channel, end-user cohorts, product typologies, therapeutic areas, and manufacturer categories, and quality assurance processes to verify consistency. Where gaps existed, targeted follow-up interviews and document reviews were executed to close informational deficits and ensure robust conclusions.

A strategic synthesis highlighting how formulation differentiation, supply chain robustness, and targeted commercialization combine to determine sustainable market outcomes for Jiangzhiling

In closing, the Jiangzhiling tablets landscape is defined by a confluence of formulation-driven clinical opportunities and commercially material operational challenges. Extended-release technologies and strength variations offer pathways to differentiate in therapeutic areas such as hyperlipidemia and hypertension, yet success depends on harmonizing clinical evidence, regulatory compliance, and dependable supply. Distribution channels and end-user heterogeneity further require nuanced go-to-market tactics that reconcile institutional procurement cycles with the increasing influence of retail and digital pharmacies.

Looking ahead, organizations that integrate formulation innovation with resilient manufacturing footprints and adaptive channel strategies will be best positioned to navigate policy shifts, supply chain disruptions, and heightened payer scrutiny. Effective execution will hinge on disciplined segmentation, targeted evidence generation, and collaborative partnerships that enhance both product differentiation and delivery reliability. These combined actions create a defensible path to sustained adoption and long-term commercial viability for Jiangzhiling tablets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Jiangzhiling Tablets Market, by Product Type

  • 8.1. Extended-Release Tablets
    • 8.1.1. 0.5G Strength
    • 8.1.2. 1G Strength
  • 8.2. Standard Tablets
    • 8.2.1. 0.5G Strength
    • 8.2.2. 1G Strength

9. Jiangzhiling Tablets Market, by Therapeutic Area

  • 9.1. Hyperlipidemia
  • 9.2. Hypertension

10. Jiangzhiling Tablets Market, by Manufacturer Type

  • 10.1. Generics
    • 10.1.1. Domestic Generics
    • 10.1.2. Imported Generics
  • 10.2. Original Brands

11. Jiangzhiling Tablets Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Jiangzhiling Tablets Market, by End User

  • 12.1. Adults
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Jiangzhiling Tablets Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Jiangzhiling Tablets Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Jiangzhiling Tablets Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Jiangzhiling Tablets Market

17. China Jiangzhiling Tablets Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Anhui Shengkang Pharmaceutical Co., Ltd.
  • 18.6. Beijing Tong Ren Tang Co., Ltd.
  • 18.7. Harbin Pharmaceutical Group Co., Ltd.
  • 18.8. Jiangsu Kanion Pharmaceutical Co., Ltd.
  • 18.9. Jilin Yatai Pharmaceutical Co., Ltd.
  • 18.10. Livzon Pharmaceutical Group Inc.
  • 18.11. Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  • 18.12. Tasly Pharmaceutical Group Co., Ltd.
  • 18.13. Yunnan Baiyao Group Co., Ltd.
  • 18.14. Zhejiang Conba Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL JIANGZHILING TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL JIANGZHILING TABLETS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL JIANGZHILING TABLETS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA JIANGZHILING TABLETS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL JIANGZHILING TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 0.5G STRENGTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 0.5G STRENGTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 0.5G STRENGTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 1G STRENGTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 1G STRENGTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 1G STRENGTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 0.5G STRENGTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 0.5G STRENGTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 0.5G STRENGTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 1G STRENGTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 1G STRENGTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 1G STRENGTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HYPERLIPIDEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HYPERLIPIDEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY DOMESTIC GENERICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY DOMESTIC GENERICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY DOMESTIC GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY IMPORTED GENERICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY IMPORTED GENERICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY IMPORTED GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ORIGINAL BRANDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ORIGINAL BRANDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ORIGINAL BRANDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GCC JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GCC JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. GCC JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 150. GCC JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 151. GCC JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 152. GCC JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. GCC JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. G7 JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. G7 JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. G7 JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 177. G7 JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 178. G7 JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 179. G7 JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. G7 JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. NATO JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. NATO JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NATO JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 186. NATO JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 187. NATO JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 188. NATO JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. NATO JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA JIANGZHILING TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)